BR0210506A - Compostos antimicrobianos e radioprotetores - Google Patents

Compostos antimicrobianos e radioprotetores

Info

Publication number
BR0210506A
BR0210506A BR0210506-3A BR0210506A BR0210506A BR 0210506 A BR0210506 A BR 0210506A BR 0210506 A BR0210506 A BR 0210506A BR 0210506 A BR0210506 A BR 0210506A
Authority
BR
Brazil
Prior art keywords
present
formula
different
same
compounds
Prior art date
Application number
BR0210506-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Prokofievich Denisenko
Nikolay Sergeevich Sapronov
Alexander Alexandrov Tarasenko
Original Assignee
Biodiem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodiem Ltd filed Critical Biodiem Ltd
Publication of BR0210506A publication Critical patent/BR0210506A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0210506-3A 2001-06-18 2002-06-14 Compostos antimicrobianos e radioprotetores BR0210506A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001117033/15A RU2259825C9 (ru) 2001-06-18 2001-06-18 Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
PCT/AU2002/000783 WO2002102789A1 (en) 2001-06-18 2002-06-14 Antimicrobial and radioprotective compounds

Publications (1)

Publication Number Publication Date
BR0210506A true BR0210506A (pt) 2004-05-18

Family

ID=20250935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210506-3A BR0210506A (pt) 2001-06-18 2002-06-14 Compostos antimicrobianos e radioprotetores

Country Status (10)

Country Link
US (6) US20040266844A1 (cg-RX-API-DMAC10.html)
EP (4) EP2471531B1 (cg-RX-API-DMAC10.html)
JP (3) JP5138146B2 (cg-RX-API-DMAC10.html)
CN (2) CN1863788B (cg-RX-API-DMAC10.html)
AU (1) AU2002311088B2 (cg-RX-API-DMAC10.html)
BR (1) BR0210506A (cg-RX-API-DMAC10.html)
CA (1) CA2450121C (cg-RX-API-DMAC10.html)
RU (1) RU2259825C9 (cg-RX-API-DMAC10.html)
WO (1) WO2002102789A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200309750B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
CN102431408A (zh) * 2007-02-20 2012-05-02 田纳科汽车营运公司 用于精确的车辆高度的定位部件和方法
CN101077866B (zh) * 2007-05-15 2012-07-11 中国人民解放军第二军医大学 取代苯并噁唑类抗真菌化合物及其制备方法
AU2013204604B2 (en) * 2012-05-30 2016-05-19 Biodiem Limited Method of treating Scedosporium spp. infection
CN103910709A (zh) * 2014-03-05 2014-07-09 甘肃省农业科学院植物保护研究所 一种高活性化合物(e)-3-(3,4-亚甲基二氧基苯基)丙烯酸环己酰氨及其制备方法和应用
CN105875292A (zh) * 2016-04-12 2016-08-24 江苏大学 卵磷脂结合葡萄汁有孢汉逊酵母防治柑橘采后病害的方法
EP3661496A4 (en) * 2017-08-01 2021-04-21 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS WITH SUBSTITUTED NITROSTYRENE COMPOUNDS
CN109400573B (zh) * 2017-08-17 2023-04-11 中国人民解放军第二军医大学 苯并[d][1,3]二氧杂环戊烯类化合物、制备方法及其应用
CN115025073B (zh) * 2022-06-23 2024-05-07 海南大学 一种苯烯烃硝基类化合物作为群体感应抑制剂的非经典抗菌活性用途
CN116836814B (zh) * 2023-06-28 2024-01-30 贵州省草业研究所 一株内生真菌及其在提高紫花苜蓿铝耐受性中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE347818C (de) 1922-01-25 Adalbert Wagner Dr Verfahren zur Herstellung aromatischer ss-Nitropropenylverbindungen
US2233823A (en) * 1939-11-15 1941-03-04 Purdue Research Foundation Process for the reduction of arylnitroalkenes
US2762848A (en) * 1953-04-17 1956-09-11 Commercial Solvents Corp Process for chlorinating arylnitroalkenes
GB862175A (en) * 1956-09-28 1961-03-01 Ciba Ltd New benzimidazoles
FR2115089A1 (en) 1970-11-30 1972-07-07 Anvar Medicaments contg trans carbocyclic or heterocyclic - nitro ethylene cpds - as antitumour and cytoxic agents
DE2134419A1 (de) 1971-07-09 1973-01-25 Basf Ag Verfahren zur herstellung von 2-phenyl3-nitro-buttersaeure-verbindungen
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
HU179696B (en) * 1979-07-26 1982-11-29 Egyt Gyogyszervegyeszeti Gyar Plant protective compositions with antimicrobial,mainly fungicide activity and process for preparing the active substances
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1210926B (it) * 1982-08-20 1989-09-29 Farmatis Srl Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
JPS6242923A (ja) 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
ATE64854T1 (de) * 1986-05-22 1991-07-15 Atlantic Pharma Prod Zusammensetzung mit hemmender wirkung auf zumindest ein einzelliges lebewesen und/oder virus, herstellungsverfahren und anwendungen dieser zusammensetzung.
EP0447813A1 (en) * 1990-02-28 1991-09-25 GRUPPO LEPETIT S.p.A. Water soluble salts of purpuromycin and pharmaceutical formulations thereof
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
KR100460164B1 (ko) * 1995-12-04 2005-01-27 아벤티스 파마 도이칠란트 게엠베하 1-하이드록시-2-피리돈을포함하는난치성점막질환치료용약제학적조성물
PT888340E (pt) * 1996-02-13 2002-12-31 Abbott Lab Derivados de acido 4-(benzo-1,3-dioxolil)pirrolidino-3-carboxilico como antagonistas de endotelina
US5801250A (en) * 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
RU2145215C1 (ru) * 1997-04-18 2000-02-10 Денисенко Петр Прокофьевич Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
PL338678A1 (en) * 1997-08-22 2000-11-20 Merck & Co Inc Derivatives of 4-cyano-4-deformylsordacin
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
JPH11171773A (ja) * 1997-12-11 1999-06-29 Iyaku Bunshi Sekkei Kenkyusho:Kk ジヒドロ葉酸還元酵素の阻害剤
MA26628A1 (fr) * 1998-05-11 2004-12-20 Glaxo Wellcome Sa Morpholino ethers
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
JP2002524546A (ja) * 1998-09-14 2002-08-06 アボット・ラボラトリーズ 立体選択性ニトロ化合物の製造方法
RU2148215C1 (ru) 1998-12-21 2000-04-27 Конструкторское бюро "Арматура" Электродный нагреватель
CA2417500C (en) 2000-07-28 2008-11-18 Georgetown University Medical Center Erbb-2 selective small molecule kinase inhibitors
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности

Also Published As

Publication number Publication date
JP5679128B2 (ja) 2015-03-04
WO2002102789A1 (en) 2002-12-27
JP5138146B2 (ja) 2013-02-06
JP5281960B2 (ja) 2013-09-04
HK1061856A1 (en) 2004-10-08
US9045452B2 (en) 2015-06-02
EP2468276B1 (en) 2015-11-11
EP1404665A4 (en) 2007-06-27
US8158664B2 (en) 2012-04-17
US20040266844A1 (en) 2004-12-30
EP2468275A1 (en) 2012-06-27
EP2468275B1 (en) 2015-11-04
EP2468276A1 (en) 2012-06-27
JP2005511487A (ja) 2005-04-28
CN101804047A (zh) 2010-08-18
US8569363B2 (en) 2013-10-29
JP2013082719A (ja) 2013-05-09
CN1863788A (zh) 2006-11-15
EP1404665B1 (en) 2012-08-08
RU2259825C2 (ru) 2005-09-10
US20100292317A1 (en) 2010-11-18
CN101804047B (zh) 2012-12-26
ZA200309750B (en) 2005-05-25
CA2450121A1 (en) 2002-12-27
AU2002311088B2 (en) 2009-01-08
EP2471531A2 (en) 2012-07-04
US20140080876A1 (en) 2014-03-20
JP2009263372A (ja) 2009-11-12
EP2471531B1 (en) 2015-11-04
RU2259825C9 (ru) 2006-04-10
US20090012137A1 (en) 2009-01-08
CN1863788B (zh) 2010-05-12
US7825145B2 (en) 2010-11-02
CA2450121C (en) 2012-08-21
US20120225935A1 (en) 2012-09-06
US20150258059A1 (en) 2015-09-17
EP1404665A1 (en) 2004-04-07
EP2471531A3 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
ES2169811T3 (es) Nuevos derivados del acido piridonacarboxilico o sus sales y agente antibacteriano que comprende el mismo como ingrediente activo.
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
NO20021401L (no) Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR122018007328B8 (pt) composto, composição farmaceutica e uso do dito composto
NO20066041L (no) Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer
BR0108613A (pt) Novo uso de derivados de fenilheteroalquiilamina
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0412130A (pt) compostos tetracìclicos como inibidores de c-met
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0210667A (pt) Derivados de oxazolidinonas como agentes antibacterianos
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR9812148A (pt) Derivados de eritromicina 6,9-ligados em ponte

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.